Molecure announces first patient dosed in Phase I trial with novel, first-in-class dual arginase inhibitor OATD-02 for the treatment of cancer
Marcin Szumowski Chief Executive Officer Samson Fung Chief Medical Officer OATD-02 First-in-class dual arginase inhibitorMolecure announces first patient dosed in...